CN1290525C - A blood lowering botanical extract and its preparation and preparing process - Google Patents
A blood lowering botanical extract and its preparation and preparing process Download PDFInfo
- Publication number
- CN1290525C CN1290525C CN 200410020961 CN200410020961A CN1290525C CN 1290525 C CN1290525 C CN 1290525C CN 200410020961 CN200410020961 CN 200410020961 CN 200410020961 A CN200410020961 A CN 200410020961A CN 1290525 C CN1290525 C CN 1290525C
- Authority
- CN
- China
- Prior art keywords
- fenugreek seeds
- preparation
- common fenugreek
- degummed
- common
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title abstract description 13
- 230000008569 process Effects 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229920005989 resin Polymers 0.000 claims abstract description 21
- 239000011347 resin Substances 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 239000004952 Polyamide Substances 0.000 claims abstract description 7
- 239000000419 plant extract Substances 0.000 claims abstract description 7
- 229920002647 polyamide Polymers 0.000 claims abstract description 7
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 12
- 229930182470 glycoside Natural products 0.000 claims description 12
- 150000002338 glycosides Chemical class 0.000 claims description 12
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims description 7
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims 2
- 239000004793 Polystyrene Substances 0.000 claims 2
- 229920002223 polystyrene Polymers 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 2
- 244000250129 Trigonella foenum graecum Species 0.000 abstract 10
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 238000011160 research Methods 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 2
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 tincture Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a plant extract and a preparation for reducing blood sugar, and a preparation method thereof. The preparation method comprises the following key points of the major technique: pulverizing common fenugreek seeds and degummed common fenugreek seeds; extracting the common fenugreek seeds and the degummed common fenugreek seeds with ethanol; refining and purifying the common fenugreek seeds and the degummed common fenugreek seeds with a macroporous resin (MRAT) technology and a polyamide technology to obtain the common fenugreek seeds and the degummed common fenugreek seeds with more than 50% of effective parts. The present invention has the advantages of high medicinal value, wide resource, adoption of common fenugreek seeds and degummed common fenugreek seeds of low price, advanced refinement and purification process, high activity of effective parts, low dosage, controllable quality and stable product. The extract obtained by the method can be made into any dosage form of medicinal and health products for preventing and curing diabetes, which is mainly applied to the field of medical treatment and health care of diabetes prevention and cure.
Description
Technical field:
The present invention relates to a kind of hypoglycemic plant extract and uses thereof, particularly a kind of blood sugar lowering Semen Trigonellae that prevents and treats diabetes and come unstuck after Semen Trigonellae extract and preparation and uses thereof.
Background technology:
Diabetes, the traditional Chinese medical science claim " diabetes ", are a kind of common metabolism endocrinopathyes, are the clinical syndrome that caused by the h and E factor interaction (chronic, general, metabolic disease).The data of World Health Organization (WHO) shows that along with raising fat, that lack motion, aged tendency of population and diagnostic techniques, diabetes are obviously different with the amplitude that developing country increases in developed country, and American-European countries is 45%, and developing country can reach 200%.Will there be growth more than 3 times in antidiabetic drug market because of the increase of type ii diabetes sickness rate in the whole world, promptly brings up to 20,000,000,000 dollars in 2006 from 6,000,000,000 dollars of present annual turnovers.China's flower in 1994 approximately is 41,900,000,000 yuans in diabetes and cardiovascular diseases's medical expense, increases sharply to 1,216 hundred million yuan by 2000.As seen how the growth of control of diabetes and effectively the treatment diabetes be the task of top priority of health circle and the world of medicine.
Both at home and abroad researcher was more and more paid attention to its biological activity the chemical constituent of Semen Trigonellae and the pharmacological action systematic research of contrasting in the last few years, and research quantity is more and more.Preliminary study shows that the Semen Trigonellae glycosides has activity at aspects such as blood sugar lowering, anticancer, control cardiovascular and cerebrovascular disease, blood pressure lowering, antibiotic, anti inflammation and heat resolution analgesias, and research in recent years is partial to more promising blood sugar lowering, anticancer, antifungal, treatment cardiovascular and cerebrovascular disease more gradually, regulates aspect such as immunity, has very high medical value and potentiality to be exploited.Steroid sapogenin is again the primary raw material of synthesizing steroid hormone medicine in the Semen Trigonellae glycosides, the consumption of steroid sapogenin increased year by year on the international market in recent years, when the steroid sapogenin annual requirement constantly increases, the diosgenin raw material reduces day by day, seeks the steroid sapogenin new resources and is quite paid attention to.At present, domestic utilization to this resource of S mainly is to be used for glue industry.Along with the development of glue technology, FS plant husbandry and glue industry begin to take shape, and resource is very abundant.Medicinal residues FSE behind the glue is used to extract the important source material of dioscin always, and cheap, and it is high to rise in value.Our extraction and purification process research and pharmacological testing prove that the alternative FS of FSE is used for extracting the Semen Trigonellae glycosides that preparation has identical pharmacologically active.
Domestic less to research in this respect, weak foundation just seems very important to this this aboundresources, exploitation cheap, the high plant of medical value.We show the chemical research of FS and FSE, they contain identical chemical constituent and hypoglycemic activity, steroid saponin component content wherein is bigger, and the content of dioscin is higher, may be developed to a kind of new resources of medicinal plant to it good prospect is provided.It is reported that the Semen Trigonellae glycosides has blood sugar lowering, blood fat reducing, anticoagulant, prevents physiological actions such as arteriosclerosis, antiinflammatory, antitumor, raise immunity, and can increase the burst size of insulin, be used for treatment of diabetes.Be the desirable natural drug of treatment diabetes, its product is owing to meet the hope and the requirement of modern people's back to nature, and market prospect is very wide.
The traditional extraction process of FS is a solvent extraction method, but this method extraction ratio is low, it is big to pollute, active constituent content is lower, at present, the methods that adopt are macroporous adsorption resin technologies more, and this technology is one of the modernization of Chinese medicine of Tenth Five-Year Plan Period state key support and key technology of original new drug research.Have extract volume little, nonhygroscopic, make characteristics such as various dosage forms aesthetic in appearance easily, be particularly suited for granule, capsule and tablet, make thick, big, the black preparation upgrading of Chinese medicine be modern preparation.
Chinese patent CN03144071.1 has invented a kind of FS extract and production method thereof for the treatment of diabetes, obtains the FS total saponins after alcohol extraction, macroporous resin adsorption; But because the macroporous resin technology is suitable for removing water-solubility impurity, contains macroporous resin among the FS and be difficult to aldehydes matters such as isolating flavone, this technique influence the purity and the activity of Semen Trigonellae total saponins.
Chinese patent CN03118627.0 discloses the method for extracting saponin in a kind of FS seed, and this patent is a raw material with the FS seed, adopts the active substance hydrolysis to obtain the Saponin body and gets thing, through the exquisite purification of macroporous resin.But this patent does not clearly propose the effective monomer component of quality control index, and quality control standard is indeterminate.
Said extracted method or technology are blended in modern advanced science and technology in the development of Chinese medicine, have solved the medium-term and long-term problem that exists of traditional preparation technology and method of quality control.But still exist the bottleneck problem of this two aspects restriction Chinese medicine development of extraction ratio and quality standard.The present invention has adopted macroporous resin, the separation and purification of polyamide technology to obtain FS and FSE total saponins, with the effective monomer diosgenin is quality control index, the purity of total saponins and the content of active ingredient have not only been improved effectively, and set up the method for quality control of standard, FS and FSE total saponins can be developed into hypoglycemic standard extract and modern medicines preparation.
Summary of the invention:
The purpose of this project is to solve that effective site purity among FS and the FSE preparation technology is low, the content requirement and the key issues such as no crude drug, intermediate and end product quality control method of development Chinese medicine the 5th class (the former two classes) new drug that can not reach national regulation, and the preparation and the preparation method of a kind of blood sugar lowering FS and FSE extract is provided.Is that standard extract is made hypoglycemic new Chinese medicine with effective site Semen Trigonellae glycosides content greater than 50%, not only solve the long-term insoluble technical field problem of extracting effective ingredient among FS and the FSE, filled up the domestic and international blank that FS and FSE effective site is developed to the modern preparation that is used to prevent and treat diabetes.
The object of the present invention is achieved like this: FS and FSE effective site are the Semen Trigonellae glycosides through the effect experiment screening, and comprising steroidal saponin and triterpene saponin, total content is more than 50%.
Further effect experiment proves that the hypoglycemic effective ingredient of Semen Trigonellae glycosides is a diosgenin wherein, and its content is in the 0.5-20% scope.
The technical problem to be solved in the present invention provides a kind of employing macroporous resin, polyamide combination purification technique, extracts the method for preparing the Semen Trigonellae glycosides from FS and FSE.
The preparation method of effective site of the present invention, step is as follows:
(1) with FS and FSE drying, pulverizing, with 5-95% alcohol reflux 1-10 time, the 1-20 that each consumption is respectively medical material weight doubly, extraction time is 0.5-10 hour, merge extractive liquid, filters, and reclaims ethanol, concentrated extractum.
(2) with the extracting solution of (1) or add extractum after water 1-200 doubly dilutes, last resin column absorption, the volume ratio of raw material weight and resin is 1: 0.5-10, resin column footpath is 1 with the post height ratio: 1-30, with pH value be water washing, the concentration of 2-8 be 5-95% alcoholic solution eluting, flow velocity be 0.5-3.5 column volume/hour.
(3) collect ethanol elution, reclaim ethanol, obtain the ethanol elution part to there not being the alcohol flavor.
(4) with the ethanol elution part in (3), after adding water 1-200 and doubly diluting, last polyamide column chromatography is that aqueous solution and the concentration of 2-8 is 1-95% alcoholic solution eluting with pH value, collect to merge eluent, and concentrating under reduced pressure, vacuum drying, promptly.
Semen Trigonellae glycosides content can reach more than 50% among employing this law FS and the FSE, and wherein the content of effective ingredient diosgenin is in the 0.5-20% scope.
The present invention compares with traditional solvent extraction, technology is simple, do not use the volatile organic solvent of toxicity in the technological process, safe and reliable, production cost is low, environmentally safe.
Standard extract of the present invention is to make medicinal various clinical acceptable forms, comprise capsule, tablet, powder, granule, oral liquid, medicated wine, pill, pellet, soft gelatin capsule, ointment, mixture, tincture, injection etc., wherein preparations such as soft capsule, tablet, granule preferably.
The standard extract that FS of the present invention and FSE obtain according to its preparation method can directly be made preparation or be mixed and made into preparation with the medicine acceptable carrier.Described medicine acceptable carrier can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose family and derivant, alginate, gelatin, polyvinylpyrrolidone, glycerol, tween 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, dextrin, phospholipid material, kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Standard extract of the present invention and preparation are to have functions such as blood sugar lowering, cholesterol reducing, enhancing human body immunity power, are applied to prevent and treat in the medicine and health product of diabetes in preparation.
Further specify the present invention by the following examples:
Embodiment 1: the preparation method of a kind of FS and FSE
FS and FSE are 10,8 times of crude drug weight with 70% alcohol reflux 2 times, each consumption, and extraction time is 2,1 hours, and merge extractive liquid, filters, and reclaims ethanol, concentrate extractum.Extractum is added 120 times of dilutions of water, the absorption of last resin column, the volume ratio of raw material weight and resin is 1: 3, resin column footpath and post height ratio are 1: 15, water washing, the 70% alcoholic solution eluting of usefulness pH=6, flow velocity be 1 column volume/hour.Collect ethanol elution, reclaim ethanol, obtain the ethanol elution part to there not being the alcohol flavor, after adding water 1-200 and doubly diluting, last polyamide column chromatography, the ethanol elution of water and 1-70% is collected the merging eluent, concentrating under reduced pressure, vacuum drying, promptly.
Semen Trigonellae glycosides content can reach 50-99% among FS that employing this law makes and the FSE, and wherein the content of effective ingredient diosgenin is in the 0.5-20% scope.
Embodiment 2: the preparation method of a kind of FS and FSE
FS and FSE are 8,6,6 times of raw medicinal herbs weight with 90% alcohol reflux 3 times, each consumption, and extraction time is 2,1,1 hours, and merge extractive liquid, filters, and reclaims ethanol, concentrate extractum.Extractum is added 150 times of dilutions of water, the absorption of last resin column, raw material heavy with volume ratio resin be 1: 5, resin column through with the post height ratio be 1: 20, with water washing, the 90% alcoholic solution eluting of pH=8, flow velocity be 2 column volumes/hour.Collect ethanol elution, reclaim ethanol, obtain the ethanol elution part to there not being the alcohol flavor, after adding water 1-200 and doubly diluting, last polyamide column chromatography, the ethanol elution of water and 1-90% is collected the merging eluent, concentrating under reduced pressure, vacuum drying, promptly.
Semen Trigonellae glycosides content can reach 50-99% among FS that employing this law makes and the FSE, and wherein the content of effective ingredient diosgenin is in the 0.5-20% scope.
Claims (4)
1, a kind of hypoglycemic plant extract is characterized in that preparing according to the following steps;
(1) Semen Trigonellae drying, the pulverizing after will coming unstuck, with 5-95% alcohol reflux 1-10 time, the 1-20 that each consumption is respectively medical material weight doubly, extraction time is 0.5-10 hour, merge extractive liquid, filters, and reclaims ethanol, concentrated extractum;
(2) with the extracting solution of (1) or add extractum after water 1-200 doubly dilutes, last resin column absorption, the volume ratio of raw material weight and resin is 1: 0.5-10, resin column footpath is 1 with the post height ratio: 1-30, with pH value be water washing, the concentration of 2-8 be 5-95% alcoholic solution eluting, flow velocity be 0.5-3.5 column volume/hour;
(3) collect ethanol elution, reclaim ethanol, obtain the ethanol elution part to there not being the alcohol flavor;
(4) with the ethanol elution part in (3), after adding water 1-200 and doubly diluting, last polyamide column chromatography is that aqueous solution and the concentration of 2-8 is 1-95% alcoholic solution eluting with pH value, collect to merge eluent, and concentrating under reduced pressure, vacuum drying, promptly;
Semen Trigonellae glycosides content reaches 50%-99% in the Semen Trigonellae extract after employing this law is come unstuck, and wherein the content of effective ingredient diosgenin is in the 0.5-20% scope.
2. blood sugar lowering plant extract according to claim 2 is characterized in that described resin is synthetic by the polystyrene series or the isobutene. series of polystyrene series, modification.
3. blood sugar lowering plant extract according to claim 1 is characterized in that this extract directly makes preparation or be mixed and made into capsule, tablet, powder, granule, oral liquid, medicated wine, pill, pellet, soft gelatin capsule, ointment, mixture, tincture or injection with its acceptable carrier.
4, according to the application of the arbitrary described blood sugar lowering plant extract of claim 1-3 in the diabetes medicine that preparation control a variety of causes causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410020961 CN1290525C (en) | 2004-07-13 | 2004-07-13 | A blood lowering botanical extract and its preparation and preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410020961 CN1290525C (en) | 2004-07-13 | 2004-07-13 | A blood lowering botanical extract and its preparation and preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593512A CN1593512A (en) | 2005-03-16 |
| CN1290525C true CN1290525C (en) | 2006-12-20 |
Family
ID=34663302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410020961 Expired - Fee Related CN1290525C (en) | 2004-07-13 | 2004-07-13 | A blood lowering botanical extract and its preparation and preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1290525C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006046041A1 (en) * | 2004-10-27 | 2006-05-04 | Orexo Ab | New pharmaceutical formulations useful in the treatment of insomnia |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360145C (en) * | 2005-08-25 | 2008-01-09 | 吉林大学 | Fenugreek extract and its preparation method and application |
| CN102552299B (en) * | 2011-11-23 | 2014-07-02 | 大连医科大学 | Application of dioscin in preparing medicament for preventing and treating diabetes mellitus |
| CN104862079B (en) * | 2015-05-27 | 2017-10-27 | 天水师范学院 | A kind of method for extracting faenum graecum blade essential oil |
-
2004
- 2004-07-13 CN CN 200410020961 patent/CN1290525C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006046041A1 (en) * | 2004-10-27 | 2006-05-04 | Orexo Ab | New pharmaceutical formulations useful in the treatment of insomnia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593512A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100560083C (en) | A preparation method for extracting and purifying total saponins from Chinese medicine Panax notoginseng | |
| CN1413724A (en) | Brain active substance for preventing and treating encephalopathy and improving intelligence and preparation method thereof | |
| CN110051726A (en) | The preparation method and application of general flavone and total starches in a kind of Qingqian Willow leaf | |
| CN101181354B (en) | Fructus schizandrae chemical composition group extract and preparation technique | |
| CN101953866A (en) | Preparation method of white-backed pseudo-ginseng total flavonoid as well as application | |
| CN103058978B (en) | Method for synchronized preparation of pinocembrin and 2', 4'-dihydroxy chalcone from oxytropis falcate bunge | |
| CN1290525C (en) | A blood lowering botanical extract and its preparation and preparing process | |
| CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN101032537A (en) | Gynura procumbens (Lour.) Merr. Flavonoid substances preparing method and the application | |
| CN102134268A (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN1686420A (en) | Baici plant fruit extract, its preparation method and application | |
| CN101301374A (en) | A preparation method of loquat leaf total flavonoids and its hypoglycemic and hypolipidemic functions | |
| CN101874841A (en) | Total glycosides extractive of morinda plants, as well as preparation method and application thereof | |
| CN101537052A (en) | Hubei caval vine general flavone extract as well as preparation method and application thereof | |
| CN109575102A (en) | The application of trilliaceae total steroidal saponin and wherein steroid saponin compound in preparation treatment ulcerative colitis drug | |
| CN103800418B (en) | Composition for promoting blood circulation and stopping pain, capsule preparation technology and application thereof | |
| CN1740184A (en) | A process for extracting secoiridoid glycosides from Gentiana medicinal plants | |
| CN101322734B (en) | Total Codonopsis saponins with anti-inflammatory and immune effects and preparation method thereof | |
| CN1730027A (en) | Method for preparing anti-hepatitis active part from swertia main pharmaceutical plant | |
| CN101278974A (en) | Cinnamon saponins extract, preparation method and application thereof | |
| CN1261111C (en) | A preparation method of oral medicine for treating depression | |
| CN106038619B (en) | A kind of ginkgo biloba p.e and preparation method thereof | |
| CN102274254B (en) | Preparation method of alligator alternanthera effective fraction extract | |
| CN1628754A (en) | Local externally applied itch stopping garlic paint |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Cui Jingbai Assignor: Zhao Yuqing Contract fulfillment period: 2010.1.6 to 2015.1.5 Contract record no.: 2010120000005 Denomination of invention: A blood lowering botanical extract and its preparation and preparing process Granted publication date: 20061220 License type: Exclusive license Record date: 2010.1.19 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2010.1.6 TO 2015.1.5; CHANGE OF CONTRACT Name of requester: TIANJIN DUUGOOD TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20100119 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061220 Termination date: 20180713 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |